{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["COVID-19", "Molecular docking", "Molecular dynamics", "Repositioned drugs", "SARS-CoV-2 main protease"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "33387249", "DateCompleted": {"Year": "2021", "Month": "06", "Day": "28"}, "DateRevised": {"Year": "2022", "Month": "12", "Day": "07"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "01", "Day": "02"}], "Language": ["eng"], "ELocationID": ["10.1007/s10930-020-09945-6"], "Journal": {"ISSN": "1875-8355", "JournalIssue": {"Volume": "40", "Issue": "3", "PubDate": {"Year": "2021", "Month": "Jun"}}, "Title": "The protein journal", "ISOAbbreviation": "Protein J"}, "ArticleTitle": "In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors.", "Pagination": {"StartPage": "296", "EndPage": "309", "MedlinePgn": "296-309"}, "Abstract": {"AbstractText": ["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emanating human infectious coronavirus that causes COVID-19 disease. On 11th March 2020, it has been announced as a pandemic by the World Health Organization (WHO). Recently, several repositioned drugs have been subjected to clinical investigations as anti-COVID-19 drugs. Here, in silico drug discovery tools were utilized to evaluate the binding affinities and features of eighteen anti-COVID-19 drug candidates against SARS-CoV-2 main protease (M<sup>pro</sup>). Molecular docking calculations using Autodock Vina showed considerable binding affinities of the investigated drugs with docking scores ranging from\u2009-\u20095.3 to\u2009-\u20098.3\u00a0kcal/mol, with higher binding affinities for HIV drugs compared to the other antiviral drugs. Molecular dynamics (MD) simulations were performed for the predicted drug-M<sup>pro</sup> complexes for 50\u00a0ns, followed by binding energy calculations utilizing molecular mechanics-generalized Born surface area (MM-GBSA) approach. MM-GBSA calculations demonstrated promising binding affinities of TMC-310911 and ritonavir towards SARS-CoV-2 M<sup>pro</sup>, with binding energy values of\u2009-\u200952.8 and\u2009-\u200949.4\u00a0kcal/mol, respectively. Surpass potentialities of TMC-310911 and ritonavir are returned to their capabilities of forming multiple hydrogen bonds with the proximal amino acids inside M<sup>pro</sup>'s binding site. Structural and energetic analyses involving root-mean-square deviation, binding energy per-frame, center-of-mass distance, and hydrogen bond length demonstrated the stability of TMC-310911 and ritonavir inside the M<sup>pro</sup>'s active site over the 50\u00a0ns MD simulation. This study sheds light on HIV protease drugs as prospective SARS-CoV-2 M<sup>pro</sup> inhibitors."]}, "AuthorList": [{"Identifier": ["0000-0003-4819-2040"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Computational Chemistry Laboratory, Chemistry Department, Faculty of Science, Minia University, Minia, 61519, Egypt. m.ibrahim@compchem.net."}], "LastName": "Ibrahim", "ForeName": "Mahmoud A A", "Initials": "MAA"}, {"Identifier": ["0000-0003-3527-0126"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Computational Chemistry Laboratory, Chemistry Department, Faculty of Science, Minia University, Minia, 61519, Egypt."}], "LastName": "Abdelrahman", "ForeName": "Alaa H M", "Initials": "AHM"}, {"Identifier": ["0000-0002-6486-9835"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia."}], "LastName": "Allemailem", "ForeName": "Khaled S", "Initials": "KS"}, {"Identifier": ["0000-0002-1491-6402"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia."}], "LastName": "Almatroudi", "ForeName": "Ahmad", "Initials": "A"}, {"Identifier": ["0000-0002-5509-9875"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biology, College of Science, King Khalid University, Abha, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Department of Botany & Microbiology, Faculty of Science, South Valley University, Qena, Egypt."}], "LastName": "Moustafa", "ForeName": "Mahmoud F", "Initials": "MF"}, {"Identifier": ["0000-0002-0343-4969"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chemistry of Medicinal Plants Department, National Research Centre, 33 El-Bohouth St., Dokki, Giza, Egypt."}], "LastName": "Hegazy", "ForeName": "Mohamed-Elamir F", "Initials": "MF"}], "GrantList": [{"GrantID": "5480", "Agency": "Science and Technology Development Fund", "Country": ""}, {"GrantID": "7972", "Agency": "Science and Technology Development Fund", "Country": ""}, {"GrantID": "R.G.P 2/90/41", "Agency": "King Khalid University", "Country": ""}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "Netherlands", "MedlineTA": "Protein J", "NlmUniqueID": "101212092", "ISSNLinking": "1572-3887"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Protease Inhibitors"}, {"RegistryNumber": "EC 3.4.22.28", "NameOfSubstance": "Coronavirus 3C Proteases"}], "MeshHeadingList": [{"QualifierName": ["enzymology", "genetics"], "DescriptorName": "COVID-19"}, {"QualifierName": ["antagonists & inhibitors", "chemistry"], "DescriptorName": "Coronavirus 3C Proteases"}, {"QualifierName": [], "DescriptorName": "Drug Discovery"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": ["chemistry"], "DescriptorName": "Protease Inhibitors"}, {"QualifierName": ["enzymology"], "DescriptorName": "SARS-CoV-2"}, {"QualifierName": [], "DescriptorName": "COVID-19 Drug Treatment"}], "CoiStatement": "The authors declare that they have no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Zhou P, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270\u2013273. doi: 10.1038/s41586-020-2012-7.", "ArticleIdList": ["10.1038/s41586-020-2012-7", "PMC7095418", "32015507"]}, {"Citation": "Wu F, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265\u2013269. doi: 10.1038/s41586-020-2008-3.", "ArticleIdList": ["10.1038/s41586-020-2008-3", "PMC7094943", "32015508"]}, {"Citation": "Gorbalenya AE, et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5:536\u2013544. doi: 10.1038/s41564-020-0695-z.", "ArticleIdList": ["10.1038/s41564-020-0695-z", "PMC7095448", "32123347"]}, {"Citation": "Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91\u201398. doi: 10.1016/j.jare.2020.03.005.", "ArticleIdList": ["10.1016/j.jare.2020.03.005", "PMC7113610", "32257431"]}, {"Citation": "Khan SA, Zia K, Ashraf S, Uddin R, Ul-Haq Z. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach. J Biomol Struct Dyn. 2020 doi: 10.1080/07391102.2020.1751298.", "ArticleIdList": ["10.1080/07391102.2020.1751298", "32238094"]}, {"Citation": "Tazikeh-Lemeski E, Moradi S, Raoufi R, Shahlaei M, Janlou MAM, Zolghadri S. Targeting SARS-COV-2 non-structural protein 16: a virtual drug repurposing study. J Biomol Struct Dyn. 2020 doi: 10.1080/07391102.2020.1779133.", "ArticleIdList": ["10.1080/07391102.2020.1779133", "PMC7332864", "32573355"]}, {"Citation": "Ibrahim MAA, Abdelrahman AHM, Hegazy MF. In-silico drug repurposing and molecular dynamics puzzled out potential SARS-CoV-2 main protease inhibitors. J Biomol Struct Dyn. 2020;1:12. doi: 10.1080/07391102.2020.1791958.", "ArticleIdList": ["10.1080/07391102.2020.1791958", "PMC7441803", "32684114"]}, {"Citation": "Harrison C. Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020;38:379\u2013381. doi: 10.1038/d41587-020-00003-1.", "ArticleIdList": ["10.1038/d41587-020-00003-1", "32205870"]}, {"Citation": "Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. Science. 2020;367:1412\u20131413. doi: 10.1126/science.367.6485.1412.", "ArticleIdList": ["10.1126/science.367.6485.1412", "32217705"]}, {"Citation": "Rosa SGV, Santos WC. Clinical trials on drug repositioning for COVID-19 treatment. Rev Panam Salud Publ. 2020;44:e40. doi: 10.26633/RPSP.2020.40.", "ArticleIdList": ["10.26633/RPSP.2020.40", "PMC7105280", "32256547"]}, {"Citation": "Yin W, et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science. 2020;368:1499\u20131504. doi: 10.1126/science.abc1560.", "ArticleIdList": ["10.1126/science.abc1560", "PMC7199908", "32358203"]}, {"Citation": "Beigel JH, et al. Remdesivir for the treatment of covid-19 - preliminary report. N Engl J Med. 2020 doi: 10.1056/NEJMoa2007764.", "ArticleIdList": ["10.1056/NEJMoa2007764", "32649078"]}, {"Citation": "Administration FD (2020) Coronavirus (COVID-19) Update: FDA issues emergency use authorization for potential COVID-19 treatment. vol. 1."}, {"Citation": "Ibrahim MAA, Abdeljawaad KAA, Abdelrahman AHM, Hegazy MF. Natural-like products as potential SARS-CoV-2 M(pro) inhibitors: in-silico drug discovery. J Biomol Struct Dyn. 2020 doi: 10.1080/07391102.2020.1790037.", "ArticleIdList": ["10.1080/07391102.2020.1790037", "PMC7443551", "32643529"]}, {"Citation": "Kandeel M, Abdelrahman AHM, Oh-Hashi K, Ibrahim A, Venugopala KN, Morsy MA, Ibrahim MAA. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease. J Biomol Struct Dyn. 2020 doi: 10.1080/07391102.2020.1784291.", "ArticleIdList": ["10.1080/07391102.2020.1784291", "PMC7332862", "32597315"]}, {"Citation": "Liu Z, et al. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J Med Virol. 2020;92:595\u2013601. doi: 10.1002/jmv.25726.", "ArticleIdList": ["10.1002/jmv.25726", "PMC7228221", "32100877"]}, {"Citation": "Cimolai N. Potentially repurposing adamantanes for COVID-19. J Med Virol. 2020;92:531\u2013532. doi: 10.1002/jmv.25752.", "ArticleIdList": ["10.1002/jmv.25752", "32176361"]}, {"Citation": "Jin Z, et al. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289\u2013293. doi: 10.1038/s41586-020-2223-y.", "ArticleIdList": ["10.1038/s41586-020-2223-y", "32272481"]}, {"Citation": "Riva L, et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020 doi: 10.1038/s41586-020-2577-1.", "ArticleIdList": ["10.1038/s41586-020-2577-1", "PMC7603405", "32707573"]}, {"Citation": "Cavasotto CN, Di Filippo JI. In silico drug repurposing for COVID-19: targeting SARS-CoV-2 proteins through docking and consensus ranking. Mol Inform. 2020 doi: 10.1002/minf.202000115.", "ArticleIdList": ["10.1002/minf.202000115", "32722864"]}, {"Citation": "Alves VM, et al. QSAR modeling of SARS-CoV Mpro inhibitors identifies sufugolix, cenicriviroc, proglumetacin, and other drugs as candidates for repurposing against SARS-CoV-2. Mol Inform. 2020 doi: 10.1002/minf.202000113.", "ArticleIdList": ["10.1002/minf.202000113", "33405340"]}, {"Citation": "Battisti V, Wieder O, Garon A, Seidel T, Urban E, Langer T. A computational approach to identify potential novel inhibitors against the coronavirus SARS-CoV-2. Mol Inform. 2020 doi: 10.1002/minf.202000090.", "ArticleIdList": ["10.1002/minf.202000090", "PMC7583376", "32721082"]}, {"Citation": "Ibrahim MAA, et al. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors. Comput Biol Med. 2020;126:104046\u2013104058. doi: 10.1016/j.compbiomed.2020.104046.", "ArticleIdList": ["10.1016/j.compbiomed.2020.104046", "PMC7543985", "33065388"]}, {"Citation": "Muralidharan N, Sakthivel R, Velmurugan D, Gromiha MM. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19. J Biomol Struct Dyn. 2020 doi: 10.1080/07391102.2020.1752802.", "ArticleIdList": ["10.1080/07391102.2020.1752802", "32248766"]}, {"Citation": "Ancy I, Sivanandam M, Kumaradhas P. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study. J Biomol Struct Dyn. 2020 doi: 10.1080/07391102.2020.1786459.", "ArticleIdList": ["10.1080/07391102.2020.1786459", "PMC7441795", "32627689"]}, {"Citation": "Wishart DS, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006;34:D668\u2013672. doi: 10.1093/nar/gkj067.", "ArticleIdList": ["10.1093/nar/gkj067", "PMC1347430", "16381955"]}, {"Citation": "Wishart DS, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46:D1074\u2013D1082. doi: 10.1093/nar/gkx1037.", "ArticleIdList": ["10.1093/nar/gkx1037", "PMC5753335", "29126136"]}, {"Citation": "Hawkins PC, Skillman AG, Warren GL, Ellingson BA, Stahl MT. Conformer generation with OMEGA: algorithm and validation using high quality structures from the protein databank and cambridge structural database. J Chem Inf Model. 2010;50:572\u2013584. doi: 10.1021/ci100031x.", "ArticleIdList": ["10.1021/ci100031x", "PMC2859685", "20235588"]}, {"Citation": "OMEGA (2013), 2.5.1.4 edn. OpenEye Scientific Software, Santa Fe, NM, USA"}, {"Citation": "SZYBKI OpenEye Scientific Software: Santa Fe, NM, USA."}, {"Citation": "Gordon JC, Myers JB, Folta T, Shoja V, Heath LS, Onufriev A. H++: a server for estimating pKas and adding missing hydrogens to macromolecules. Nucleic Acids Res. 2005;33:W368\u2013W371. doi: 10.1093/nar/gki464.", "ArticleIdList": ["10.1093/nar/gki464", "PMC1160225", "15980491"]}, {"Citation": "Forli S, Huey R, Pique ME, Sanner MF, Goodsell DS, Olson AJ. Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Nat Protoc. 2016;11:905\u2013919. doi: 10.1038/nprot.2016.051.", "ArticleIdList": ["10.1038/nprot.2016.051", "PMC4868550", "27077332"]}, {"Citation": "Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455\u2013461. doi: 10.1002/jcc.21334.", "ArticleIdList": ["10.1002/jcc.21334", "PMC3041641", "19499576"]}, {"Citation": "Case DA, et al. AMBER 2016. San Francisco: University of California; 2016."}, {"Citation": "Maier JA, Martinez C, Kasavajhala K, Wickstrom L, Hauser KE, Simmerling C. ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB. J Chem Theory Comput. 2015;11:3696\u20133713. doi: 10.1021/acs.jctc.5b00255.", "ArticleIdList": ["10.1021/acs.jctc.5b00255", "PMC4821407", "26574453"]}, {"Citation": "Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general amber force field. J Comput Chem. 2004;25:1157\u20131174. doi: 10.1002/jcc.20035.", "ArticleIdList": ["10.1002/jcc.20035", "15116359"]}, {"Citation": "Bayly CI, Cieplak P, Cornell W, Kollman PA. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model. J Phys Chem. 1993;97:10269\u201310280. doi: 10.1021/j100142a004.", "ArticleIdList": ["10.1021/j100142a004"]}, {"Citation": "Frisch MJ, et al. Gaussian 09, Revision. E01. Wallingford CT, USA: Gaussian Inc.; 2009."}, {"Citation": "Massova I, Kollman PA. Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding. Perspect Drug Discov Des. 2000;18:113\u2013135. doi: 10.1023/A:1008763014207.", "ArticleIdList": ["10.1023/A:1008763014207"]}, {"Citation": "McKee DL, Sternberg A, Stange U, Laufer S, Naujokat C. Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol Res. 2020;157:104859. doi: 10.1016/j.phrs.2020.104859.", "ArticleIdList": ["10.1016/j.phrs.2020.104859", "PMC7189851", "32360480"]}, {"Citation": "de Ruyck J, Brysbaert G, Blossey R, Lensink MF. Molecular docking as a popular tool in drug design, an in silico travel. Adv Appl Bioinform Chem. 2016;9:1\u201311. doi: 10.2147/AABC.S105289.", "ArticleIdList": ["10.2147/AABC.S105289", "PMC4930227", "27390530"]}, {"Citation": "Yoshino R, Yasuo N, Sekijima M. Identification of key interactions between SARS-CoV-2 main protease and inhibitor drug candidates. Sci Rep. 2020;10:12493. doi: 10.1038/s41598-020-69337-9.", "ArticleIdList": ["10.1038/s41598-020-69337-9", "PMC7385649", "32719454"]}, {"Citation": "Ghahremanpour MM, et al. Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2. ACS Med Chem Lett. 2020 doi: 10.1021/acsmedchemlett.0c00521.", "ArticleIdList": ["10.1021/acsmedchemlett.0c00521", "PMC7605328", "33324471"]}, {"Citation": "Nutho B, et al. Why are lopinavir and ritonavir effective against the newly emerged coronavirus 2019? atomistic insights into the inhibitory. Mech Biochem. 2020;59:1769\u20131779. doi: 10.1021/acs.biochem.0c00160.", "ArticleIdList": ["10.1021/acs.biochem.0c00160", "32293875"]}], "ReferenceList": []}], "History": [{"Year": "2020", "Month": "11", "Day": "25"}, {"Year": "2021", "Month": "1", "Day": "3", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "6", "Day": "29", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "1", "Day": "2", "Hour": "12", "Minute": "10"}, {"Year": "2021", "Month": "1", "Day": "2"}], "PublicationStatus": "ppublish", "ArticleIdList": ["33387249", "PMC7776322", "10.1007/s10930-020-09945-6", "10.1007/s10930-020-09945-6"]}}], "PubmedBookArticle": []}